The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Systemic Lupus Erythematosus
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
-
UCSD - Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California, United States, 92037
East Bay Rheumatology Medical Group, Inc, San Leandro, California, United States, 94578
Providence Saint John's Medical Foundation, Santa Monica, California, United States, 90404
Clinical Research of West Florida, Inc. (Clearwater), Clearwater, Florida, United States, 33765
UF Health Deerwood Park, Jacksonville, Florida, United States, 32256
Life Clinical Trials, Margate, Florida, United States, 33063
Clinical Research Center of Pompano, Pompano Beach, Florida, United States, 33064
Emory University School of Medicine- Grady Campus, Atlanta, Georgia, United States, 30303
Atlanta Research Center for Rheumatology, Marietta, Georgia, United States, 30060
Local Institution - 0089, Orland Park, Illinois, United States, 60467
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 75 Years
ALL
No
Bristol-Myers Squibb,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2027-12-17